Capillary Artemisia (Artemisia capillaris Thunb.): A Comprehensive Reference
1. Identity, Botanical Classification, and Common Names
Artemisia capillaris Thunb. (known as Yin-Chen in Chinese) is a traditional medicinal herb with a wide spectrum of pharmacological properties ranging from effects against liver dysfunction to treatments of severe cirrhosis and cancer. The plant belongs to the family Asteraceae, which is the largest and most widely distributed genus of the plant family Asteraceae, encompassing more than 400 species.
Artemisia capillaris is the above-ground dried part of Artemisia capillaris Thunb. or Artemisia scoparia Waldst. et Kit., a natural medicinal plant. The two species are sometimes used interchangeably in traditional practice, though their phytochemical profiles differ in important respects: A. scoparia contains higher levels of the essential active compound scoparone, whereas chlorogenic acid is abundant in A. capillaris.
The herb is known by a variety of names across languages and traditions. Common names include Chinese Moxa Weed, Capillaris, Oriental Wormwood, Herba Artemisiae Capillaris, and Herba Artemisiae Yinchenha. The botanical name is Artemisia capillaris, and its Chinese / Pin Yin name is Yin Chen Hao.
The herb's name in TCM changes depending on the season of harvest. It can have two different names depending on when it is harvested: if harvested in the autumn it is known as Yin Chen Hao, and when harvested in the summer it is known as Mian Yin Chen. This distinction is pharmacologically significant: the harvested time and region of the plant also affect the chemical compositions of bioactive compounds. Both capillarisin and scoparone (6,7-dimethylesculetin) content reach peak levels in the leaf of A. capillaris at the end of July, while the maximal level of capillarisin and scoparone is detected in the capitulum in early August and early September, respectively. The appropriate time to harvest A. capillaris is therefore an important consideration that affects pharmacological actions, including possible toxicity from scoparone.
Common Forms and Preparations
The herb is consumed and studied in multiple preparations. In modern herbal medicine, Artemisia capillaris is frequently used in teas, tinctures, and extracts to assist with liver detox, skin health, and immune modulation. In research, preparations include aqueous (water) decoctions, ethanol extracts, and isolated fractions. The drug is described in Chinese pharmacopoeia as a natural medicinal plant with pharmacological effects of heat-clearing and biliary-promoting. The polysaccharide fraction has also been studied for specific properties, as described in preclinical models below.
2. Traditional and Historical Use
Traditional Chinese Medicine
The original uses of Artemisia capillaris Thunb. in traditional Chinese medicine included the treatment of pyrexia (fever), jaundice, and dysuria. Traditional Chinese medicine describes capillary artemisia as bitter, acrid and slightly cold, able to remove damp heat from the spleen, stomach, liver and gall bladder. It is considered an important drug for treating jaundice.
The classical formula Yin-Chen-Hao-Tang (Artemisia Capillaris Decoction) is central to the plant's historical role. Artemisia capillaris Thunb. (Yin-Cen-Hao), Gardenia jasminoides Ellis (Zhi-Zi), and Rheum officinale Baill (Da-Huang) were combined to prepare the formulation named Yin-Chen-Hao-Tang, which was first recorded in the book Shang-Han-Lun (Treatise on Cold Damage Diseases) approximately two thousand years ago. The weight ratio of each herb component recorded in the book was 6:3:2 for Artemisia capillaris Thunb., Gardenia jasminoides Ellis, and Rheum officinale Baill. The classical dose of Artemisia capillaris within this formula is documented as 18 grams, combined with Zhi Zi (Gardenia, 9 grams) and Da Huang (Rhubarb root, 6 grams).
Yin Chen Hao Tang is the classical Chinese herbal formula for clearing Damp-Heat from the Liver and Gallbladder to treat jaundice (huang dan) and liver conditions. Originating from Zhang Zhongjing's Shang Han Lun, it is the primary formula for yang-type jaundice characterised by bright yellow-orange skin and eyes from Liver-Gallbladder Damp-Heat.
Within TCM, the plant was also used in a second classical formula for a contrasting pattern: Yin Chen Si Ni Tang (Artemisia and Frigid Extremities Decoction) treats yin-type jaundice, the opposite of the yang-type jaundice addressed by Yin Chen Hao Tang, pairing Yin Chen with warming herbs like Fu Zi (Aconite) and Gan Jiang (Dried Ginger) to warm Yang and resolve Cold-Dampness.
Korean and Japanese Traditions
In Korea, A. capillaris has been used as a food additive and as a folk medicine to cure inflammation, microbial infections, malaria, and hepatitis. It is also a famous traditional Chinese medicinal herb used for the treatment of epidemic hepatitis. An infusion has been used internally across East Asian traditions in the treatment of jaundice, hepatitis, gall bladder complaints, and feverish illnesses.
3. Key Phytochemical Constituents
The plant mainly contains coumarins, flavonoids, organic acids, volatile oils, terpenoids, and other chemical components. The most thoroughly studied bioactive compounds are summarized below.
Coumarins: Scoparone and Scopoletin
Scoparone (6,7-dimethoxycoumarin; also known as 6,7-dimethylesculetin) is considered the primary active compound. Artemisia capillaris has displayed favourable effects in the treatment of jaundice, inflammation of the liver, and cholecystitis for thousands of years. The biosynthesis of scoparone, the major active component in A. capillaris, has recently been elucidated through transcriptomic and metabolomic approaches.
Scoparone decreases the levels of interleukin (IL)-1-beta, IL-6, and TNF-alpha due to its anti-inflammatory activities, and suppresses the levels of iNOS and COX-2 in IFN-gamma- or LPS-stimulated cells. Moreover, scoparone inhibits the transcriptional activity of peroxisome proliferator-activated receptor gamma (PPARγ) and downregulation of its target genes, an effect that leads to inhibition of triglyceride accumulation in mature adipocytes. The choleretic effect of scoparone is indirectly potentiated by cytochrome P450 1A2 via the bile salt export pump promoter.
Scopoletin is a related coumarin. Scopoletin isolated from A. capillaris contributes to bile secretion similarly to scoparone but has no effect on bile acid and cholesterol secretion.
Chromone Derivative: Capillarisin
Capillarisin is derived naturally from chromone. The compound has antioxidant, anti-inflammatory, and potential antitumor properties. Together with scoparone, capillarisin has been identified in multiple extraction studies as one of the most consistently present and pharmacologically active compounds in the plant.
Terpenoid Compound: Capillin
Capillin is a terpenoid compound found in A. capillaris. GC-MS and TLC analyses have identified compounds including capillin and piperitone, along with α-pinene, β-pinene, and β-caryophyllene, which hold strong antibacterial potential. Extraction of capillin from A. capillaris has been rarely reported, and the pharmacokinetics of capillin remain unknown.
Organic and Phenolic Acids
The contents of six compounds — chlorogenic acid, caffeic acid, isochlorogenic acid A, hyperoside, isoquercitrin, and scoparone — have been simultaneously assayed in A. capillaris. Chlorogenic acid (21.06 ± 0.08 mg/g) and isochlorogenic acid A (43.14 ± 0.12 mg/g) have been identified as major components.
Additional Identified Constituents
Artemisia capillaris Thunb. has been experimentally verified to contain bioactive compounds including scoparone (6,7-dimethylesculetin), β-sitosterol, capillarin, capillarisin, cirsimaritin, quercetin, and chlorogenic acid. GC-MS and TLC have also identified 1-borneol, camphor, achillin, and coumarin with potential anticarcinogenic properties.
Pharmacokinetics of Key Compounds
The choleretic, anti-inflammatory, and antioxidant effects of A. capillaris are mainly attributable to scoparone, scopoletin, capillarisin, capillin, and chlorogenic acids, while antidiabetic, antisteatotic, and antitumor effects are attributed to scopoletin, capillarisin, capillin, and chlorogenic acids. Considering the relatively low plasma concentration detected from scopoletin, antitumor properties of A. capillaris consequently in part come from capillarisin, capillin, and chlorogenic acids. Despite the unknown pharmacokinetics of capillin, all compounds could reach the corresponding Cmax within an hour and diminished to half-concentration within 5 hours, except for chlorogenic acids, which could last more than a month.
For antisteatotic, antidiabetic, and antitumor activities attributed to capillarisin, capillin, and chlorogenic acids with relatively low Cmax and a long half-life, dosing may need to be adjusted to suit a particular therapeutic purpose. Pharmacokinetic parameters of some bioactive compounds in A. capillaris, including scoparone and capillarisin, were acquired from the herbal formula Yin-Chen-Hao-Tang, which significantly altered the pharmacokinetics of these bioactive compounds.
4. Mechanisms of Action
Published studies have revealed that pharmacological effects are attributed to verified bioactive compounds such as scoparone, scopoletin, capillarisin, capillin, and chlorogenic acids. These compounds induce pharmacological effects including anti-inflammatory, antioxidant, choleretic, antisteatotic, antidiabetic, and antitumor activities, and synergistically contribute to the therapeutic effects of A. capillaris.
With respect to anti-hepatitis and liver-protective effects specifically: the choleretic, anti-inflammatory, and antioxidant effects that partly come from scoparone and scopoletin contributing to anti-hepatitis treatment could achieve a therapeutic window within a relatively short time.
In preclinical models of fibrosis: the β-sitosterol component derived from A. capillaris alleviates dimethylnitrosamine-induced hepatofibrosis in mice. In a model of bile duct ligation-induced cholestatic fibrosis, aqueous extract of A. capillaris suppresses the expression of fibrogenic factors, including alpha-smooth muscle actin (α-SMA), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β), and significantly reduces cholestatic markers malondialdehyde (MDA) and hydroxyproline after 2 weeks of treatment in rats.
Anti-inflammatory activity in the context of the hepatocellular carcinoma (HCC) cell environment has also been described: aqueous extract of A. capillaris has been shown to inhibit interleukin-1 receptor (IL-1R)- and tumor necrosis factor receptor (TNF-α)-induced cytotoxicity and ethanol-induced apoptosis of liver cells. A. capillaris also inhibited inflammatory response through preventing NF-kappa B activation in HCC cells.
5. Scientific Evidence by Area of Use
5.1 Liver Diseases: Hepatitis, Cholestasis, and Cirrhosis
Artemisia capillaris has been recognized as an herb with therapeutic efficacy in liver diseases and is widely used as an alternative therapy in Asia. Numerous studies have reported the antisteatotic, antioxidant, anti-inflammatory, choleretic, antiviral, antifibrotic, and antitumor activities of A. capillaris. These reports support its therapeutic potential in various liver diseases such as chronic hepatitis B virus (HBV) infection, cirrhosis, and hepatocellular carcinoma.
From Korean clinical literature, a systematic survey found that Artemisia capillaris was the most common herb identified across 31 clinical studies involving 407 patients; most involved chronic hepatitis B or C, while fewer involved acute hepatitis A. Injin-cheonggan-tang and Cheonggan Plus (CGX) were the most frequently used formulas (six studies each), with A. capillaris as the most common herb. In acute hepatitis A, herbal medicine was associated with rapid biochemical normalization and symptom resolution. In chronic hepatitis B or C, it was associated with stabilized liver function and symptom relief, although serologic responses were limited to a subset of patients. These studies, however, were largely retrospective, were mostly small in scale, and did not employ randomized controlled trial designs in all cases, limiting the strength of the evidence.
Regarding hepatitis B virus (HBV) specifically: previous investigations suggested that the antiviral effects of A. capillaris were attributable to its isolated constituents. Pumilaside A was among a series of compounds isolated from the 90% ethanol extract of A. capillaris and was discovered to have the strongest antiviral activity. Tablets prepared from A. capillaris have the potential to inhibit the replication of hepatitis B virus and thus act as a potent remedy for hepatitis B disease. The evidence for HBV replication inhibition cited in these reviews is predominantly from cell culture (in vitro) studies; large-scale controlled human trials specifically for HBV are limited.
Regarding jaundice, a 2022 pharmacodynamic and network pharmacology study investigated A. capillaris in an animal model of ANIT-induced cholestatic jaundice: Effect of ACT in treating jaundice was evaluated by biochemical assays and pathological observation using α-naphthyl isothiocyanate (ANIT)-induced mice, with mechanism investigated by integration of network pharmacology and metabolomics. After the mice with jaundice were administered ACT extract for 9 days, serum D-BIL, T-BIL, and ALP levels of the mice in the low, medium, and high dose groups decreased measurably compared to the model group. This study was preclinical (animal model only).
Polysaccharides extracted from A. capillaris have also been evaluated. Studies show that capillary artemisia can protect the liver, relax the gallbladder, and remove jaundice, providing a pharmacological basis for treating liver disease. One study investigated the protective effects of capillary artemisia polysaccharide on oxidative injury to the liver using the common bile duct ligation method in growing rats. This was a preclinical animal study.
Overall evidence strength for liver disease: The evidence base includes promising in vitro data, multiple animal model studies, and a body of clinical observational work (primarily from Asian countries), supported by one published systematic review. Large, well-designed, placebo-controlled human trials remain limited; the totality of human clinical evidence is therefore preliminary to moderate in strength.
5.2 Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome
In order to evaluate the therapeutic effect of Artemisia capillaris on NAFLD and obesity, experiments were conducted using aqueous extracts of A. capillaris to intervene in NAFLD models in vivo and in vitro. In vivo experiments were performed using high-fat diet (HFD)-fed C57BL/6 mice to induce the NAFLD model, and in vitro experiments were performed using oleic acid to induce HepG2 cells to construct an NAFLD cell model.
A. capillaris was reported to markedly decrease the accumulated fat volume in free fatty acid-treated HepG2 cells and 3T3-L1 adipocytes. A. capillaris also conspicuously improved the lipid profile including triglyceride, total cholesterol, LDL, and HDL levels in obese rats.
Recent studies have found that, in addition to its choleretic and hepatoprotective pharmacological effects, A. capillaris also has a variety of pharmacological activities such as antipyretic, anti-inflammatory, analgesic, and regulating lipid metabolism. Organic acids such as chlorogenic acid and caffeic acid contained in A. capillaris exhibited potential anti-obesity effects in mice induced by high-fat diet.
Overall evidence strength for NAFLD/metabolic syndrome: Currently limited to in vitro and animal model studies. No clinical human trials for this indication have been published.
5.3 Hepatocellular Carcinoma (HCC) — Preclinical Anticancer Activity
Artemisia capillaris has been traditionally used as a hepatoprotective and anti-inflammatory agent. In laboratory investigations, an ethanol fraction (LAC117) was extracted from the dried leaves of A. capillaris and was found to have anticancer activity and a defined mechanism of action against hepatocellular carcinoma.
LAC117 strongly suppressed the growth and proliferation of human HCC cell lines (HepG2 and Huh7). Induction of apoptosis was evidenced by the increases of cleaved caspase-3 and PARP as well as TUNEL-positive cells. The pro-apoptotic effect of LAC117 was observed by a decrease in XIAP expression and an increase in cytochrome c release via mitochondrial membrane potential. Moreover, it significantly inhibited the PI3K/AKT pathway in HCC in vivo and in vitro. LAC117 suppressed tumor growth in an ex vivo model as well as in a mouse xenograft by inducing apoptosis and inhibiting tumor cell proliferation.
The study concluded that LAC117 could not only efficiently induce apoptosis but also inhibit the growth of human HCC cells by blocking the PI3K/AKT signaling pathway, suggesting that LAC117 would be a potentially useful drug candidate against HCC.
Overall evidence strength for HCC: Currently restricted to in vitro cell line studies and mouse xenograft models. No human clinical trials have been conducted for this indication.
5.4 Atopic Dermatitis and Skin Inflammation
Artemisia capillaris has been used to treat inflammatory and hepatic disorders such as hepatic injury, hepatic fibrosis, and hepatitis. Its efficacy against atopic dermatitis (AD), an inflammatory disease, has also been evaluated. In one published study, AC was evaluated for anti-inflammatory and anti-AD effects using both in vitro and in vivo systems.
To examine the role of A. capillaris in vivo, AC (10 mg/mouse/day) was topically applied for four weeks to the back and ears of Dermatophagoides farinae-sensitized Nc/Nga mice. Protopic ointment (0.1% tacrolimus) was used as a positive control. In vitro studies revealed that A. capillaris hampered NO and cellular histamine synthesis. In Nc/Nga mice, dermatitis scores as well as hemorrhage, hypertrophy, and hyperkeratosis of the epidermis declined after topical application of A. capillaris. Plasma levels of histamine and IgE also significantly decreased after treatment. The investigators concluded that further study is warranted as a potential therapeutic option for atopic dermatitis.
Overall evidence strength for atopic dermatitis: Preclinical in vitro and animal model evidence only. No controlled human clinical trials have been published.
5.5 Psoriasis
An A. capillaris extract cream formulation (ACE) has been tested in an imiquimod-induced psoriasis model. After topical application of ACE on psoriasis-like lesion for 4 days, the epidermal thickness of the ACE-treated group was significantly lower than that of the imiquimod control group (p < .05). The expression levels of Ki-67 and intracellular adhesion molecule-1 in excised skin tissues of the ACE-treated group were also lower. All these findings suggest that ACE can be used as a promising antipsoriatic agent.
Overall evidence strength for psoriasis: Preclinical animal model only; no human clinical data published.
5.6 Sedative and CNS Effects
A mouse study cited in the pharmacological literature found that Artemisia capillaris Thunb. produces sedative-hypnotic effects in mice, which are probably mediated through potentiation of the GABAA receptor, as published in the American Journal of Chinese Medicine.
Overall evidence strength for CNS effects: Preclinical (animal) only; no human clinical evidence available.
5.7 Antimicrobial Activity
GC-MS and TLC analysis identified five compounds — α-pinene, β-pinene, β-caryophyllene, capillin, and piperitone — which hold strong antibacterial potential. Germacrene D isolated from the essential oil of A. capillaris possesses significant fumigant properties. These findings are from laboratory-based bioassay studies; no clinical antimicrobial trials in humans have been reported.
6. Body Systems Associated with Capillary Artemisia
- Hepatobiliary system: The pharmaceutical effects of A. capillaris contribute to the treatment of viral hepatitis, cirrhosis, and hepatocellular hepatoma.
- Metabolic/endocrine system: The plant's clinical applications extend to metabolic syndrome.
- Integumentary (skin) system: Clinical associations include psoriasis.
- Immune system: A. capillaris has shown anti-inflammatory effects in atopic dermatitis and chronic hepatitis B virus infection.
- Central nervous system: Preliminary preclinical data suggest sedative-hypnotic activity via GABA modulation.
- Cardiovascular system: Scoparone at 60 mg/kg daily could alleviate angiotensin II infusion-induced cardiac hypertrophy and fibrosis in mice while maintaining cardiac output. This is based solely on animal data.
- Gastrointestinal system: Yin-Chen-Hao-Tang, a formula in which A. capillaris is the principal herb, has been used in China as an anti-inflammatory and choleretic agent.
7. Dosage Forms and Reported Dosages
Dosages reported in research and traditional contexts include:
- In the classical formula Yin-Chen-Hao-Tang, Artemisia capillaris (Yin Chen) is used at a quantity of 18 grams, combined with Zhi Zi (Gardenia) at 9 grams and Da Huang (Rhubarb) at 6 grams.
- In a mouse model of atopic dermatitis, AC was administered at 10 mg/mouse/day topically for four weeks.
- A 13-week subchronic toxicity study employed oral doses of 25, 74, 222, 667, and 2000 mg/kg body weight in rats.
- High doses of 15 grams or more are documented as possibly unsafe, capable of causing numbness, tremors, irregular heartbeat, and fainting.
Regarding the clinical use of this herb, the development of A. capillaris in terms of composition or dosing schedule for more effective and efficient treatment should be considered for future clinical studies. No standardized therapeutic dose for humans has been formally established in evidence-based international guidelines.
8. Safety Considerations and Interactions
Subchronic Toxicity and Genotoxicity
Despite its ethnomedicinal benefits, sufficient background information about the long-term safety and genotoxicity of the A. capillaris extract has been limited. One study investigated the 13-week subchronic toxicity and genotoxicity of the AC extract according to OECD test guidelines. Oral administration of the AC extract at doses of 25, 74, 222, 667, and 2000 mg/kg body weight in male and female rats did not result in any significant adverse effects in food/water consumption, body weight, mortality, hematology, serum biochemistry, organ weight, or histopathology.
High-Dose Adverse Effects
When taken by mouth, yin chen is considered possibly safe at typical doses. It can cause nausea, bloating, and dizziness. High doses of 15 grams or more are possibly unsafe. These high doses can cause numbness, tremors, irregular heartbeat, and fainting.
Pyrrolizidine Alkaloids
A notable safety signal specific to A. capillaris concerns the presence of pyrrolizidine alkaloids (PAs). Pyrrolizidine alkaloids are widespread plant secondary metabolites regarded as natural toxins on account of their potential health risks for both livestock and humans. Amounts of in vivo and in vitro experiments have shown that PAs principally cause damage to the liver, some might harm the lungs via blood vessels, and some can damage the brain. They can also form a series of DNA adducts that cause genotoxicity.
It had not previously been widely reported whether PAs are present in the widely used Asteraceae plant Artemisia capillaris Thunb. A UPLC-MS/MS method was developed and validated for simultaneous determination and risk assessment of PAs in A. capillaris. Risk assessment was conducted according to the European Medicines Agency (EMA) guideline. Finally, PAs were found in 29 out of 30 samples tested, and at least two were detected in each sample; moreover, more than half of the samples exceeded the EMA baseline threshold. These findings highlight a safety consideration that warrants further regulatory and pharmacological investigation.
Harvest Time and Compositional Variability
The appropriate time to harvest A. capillaris is an important consideration that affects pharmacological actions, including possible toxicity from scoparone. The therapeutic benefits of A. capillaris are influenced by various parts of the plant and harvest time, and should be balanced based on the contents of bioactive components.
CYP450 Enzyme Interactions
Scientific evidence suggests that Artemisia compounds can alter drug metabolism through enzymatic pathways (notably the CYP450 system), potentially neutralizing treatment efficacy or exacerbating systemic toxicity. This interaction concern applies to the genus broadly, with specific enzyme interactions for A. capillaris documented preclinically: scoparone's choleretic effect is mediated in part through the cytochrome P450 1A2 pathway, suggesting that concurrent use of drugs metabolized by this enzyme system may lead to interactions. Formal drug–herb interaction studies in humans have not been published for A. capillaris specifically.
Contact Sensitization
Skin contact with A. capillaris can cause dermatitis or other allergic reactions in some people. Given that the plant belongs to the Asteraceae family, cross-reactivity with other members of this family (e.g., ragweed, chrysanthemum) is a recognized concern, though species-specific human sensitization data for A. capillaris are limited.
9. Summary of Evidence Levels
The following table summarizes the overall evidence quality across the main areas of investigation for Artemisia capillaris:
- Liver protection and anti-jaundice: Multiple preclinical studies; limited but present clinical observational and survey data from Asia. Evidence is preliminary to moderate; large randomized controlled trials are lacking.
- Antiviral (HBV): In vitro and limited clinical survey data; no large RCTs.
- NAFLD / lipid metabolism: In vitro and animal model data only; no human trials.
- Anticancer (HCC): In vitro and xenograft mouse model data only; no human trials.
- Atopic dermatitis / psoriasis: Animal model data only; no human clinical trials.
- Antimicrobial: Laboratory (in vitro) data only.
- CNS/sedative effects: Single animal study; no human data.
References
Go back